Contineum Therapeutics (NASDAQ:CTNM) Announces Quarterly Earnings ResultsMarket Beat·21 hours agoCTNM-1.65%BAC+0.36%
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD PipelinesTip Ranks·1 day ago, 01:55 PMCTNM-1.65%JNJ+0.21%
Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029TradingView·Jul 13 at 03:23 PMCTNM-1.65%JNJ+0.21%
Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 16,640 in common sharesPUBT·Jul 10 at 04:21 PMCTNM-1.65%
Contineum Therapeutics CEO Carmine N. Stengone disposes of 2,500 shares for $40,000PUBT·Jul 8 at 05:49 PMCTNM-1.65%
Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 556,791 common sharesPUBT·Jul 2 at 04:47 PMCTNM-1.65%
Contineum Therapeutics CEO Carmine Stengone sells 10,000 common shares for $160,080PUBT·Jul 1 at 06:04 PMCTNM-1.65%
Contineum launches global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis patientsPUBT·Jun 30 at 03:06 PMCTNM-1.65%
Contineum Therapeutics shareholders elect Class II directors at annual meetingPUBT·Jun 26 at 03:52 PMCTNM-1.65%
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider PotentialMarket Beat·May 22 at 07:03 AMCTNM-1.65%
Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)Tip Ranks·May 10 at 09:39 PMCTNM-1.65%
